W. Steward

Publication List Details

Period

1988 - 2007

Number

22

Co-Authors

A phase IB, open-label dose-escalating study of the oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK), in combination with FOLFOX4 chemotherapy in patients with advanced colorectal cancer (2007)

Thomas, AL, Trarbach, T, Bartel, C, Laurent, D, Henry, A, Poethig, M, ...

Background: This open-label, phase IB study was undertaken to determine the safety/toxicity profile and recommended dose of oral once-daily PTK787/ZK 222584 (PTK/ZK) combined with...

A phase IB, open-label dose-escalating study of the oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK), in combination with FOLFOX4 chemotherapy in patients with advanced colorectal cancer (2007)

Thomas, AL, Trarbach, T, Bartel, C, Laurent, D, Henry, A, Poethig, M, ...

Background: This open-label, phase IB study was undertaken to determine the safety/toxicity profile and recommended dose of oral once-daily PTK787/ZK 222584 (PTK/ZK) combined with...

A phase IB, open-label dose-escalating study of the oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK), in combination with FOLFOX4 chemotherapy in patients with advanced colorectal cancer (2007)

Thomas, AL, Trarbach, T, Bartel, C, Laurent, D, Henry, A, Poethig, M, ...

Background: This open-label, phase IB study was undertaken to determine the safety/toxicity profile and recommended dose of oral once-daily PTK787/ZK 222584 (PTK/ZK) combined with...

A phase I study of intravenous TZT-1027 administered on day 1 and day 8 of a three-weekly cycle in combination with carboplatin given on day 1 alone in patients with advanced solid tumours (2006)

Greystoke, A., Blagden, S., Thomas, A. L., Scott, E., Attard, G., Molife, R., ...

Background: TZT-1027 is a tubulin-binding drug and synthetic derivative of dolastatin-10 with cytotoxic and antivascular activity in vitro and in vivo. Studies have demonstrated anti-tumour activity...

Phase III trial of 5-fluorouracil and leucovorin plus either 3H1 anti-idiotype monoclonal antibody or placebo in patients with advanced colorectal cancer (2006)

Chong, G., Bhatnagar, A., Cunningham, D., Cosgriff, T. M., Harper, P. G., Steward, W., ...

Background: The monoclonal antibody 3H1 mimics the external structure of the carcinoembryonic antigen (CEA). It therefore has the potential, via the anti-idiotypic network, to stimulate immune...

A phase I study of intravenous TZT-1027 administered on day 1 and day 8 of a three-weekly cycle in combination with carboplatin given on day 1 alone in patients with advanced solid tumours (2006)

Greystoke, A., Blagden, S., Thomas, A. L., Scott, E., Attard, G., Molife, R., ...

Background: TZT-1027 is a tubulin-binding drug and synthetic derivative of dolastatin-10 with cytotoxic and antivascular activity in vitro and in vivo. Studies have demonstrated anti-tumour activity...

Phase II study of troxacitabine in chemotherapy-naive patients with advanced cancer of the pancreas: Gastrointestinal tumors (2005)

Lapointe, R., Létourneau, R., Steward, W., Hawkins, R. E., Batist, G., Vincent, M., ...

Background: Troxacitabine (Troxatyl™) is a novel L-enantiomer nucleoside analog with activity in pancreatic cancer xenograft models. Patients and methods: Troxacitabine 1.5 mg/m2 was administered...

NCIC-CTG phase II study of gemcitabine in patients with malignant glioma (IND.94) (2000)

Gertler, S. Z., MacDonald, D., Goodyear, M., Forsyth, P., Stewart, D. J., Belanger, K., ...

Purpose: We conducted a phase II multicentre study of gemcitabine in patients with anaplastic astrocytoma and glioblastoma multiforme at first relapse. Patients and methods: Patients with anaplastic...

A phase II trial with Docetaxel (TaxotereTM) in second line treatment with chemotherapy for advanced breast cancer: A study of the EORTC Early Clinical Trials Group (1994)

Ten Bokkel Huinink, W. W., Prove, A. M., Piccart, M., Steward, W., Tursz, T., Wanders, J., ...

Background Docetaxel, a semisynthetic analog of paclitaxel, made for the needles of the European yew, Taxus baccata, is a potentially important chemotherapeutic agent for the treatment of cancer....

EORTC joint ventures in quality control: treatment-related variables and data acquisition in chemotherapy trials (1991)

Steward, W, Blackledge, G, Verweij, J

In multicentre studies, non-compliance with the protocol may limit the chances of reaching a correct conclusion. A procedure to examine the administration of chemotherapy in multicentre EORTC...

High-dose DTIC in advanced soft-tissue sarcomas in the adult (1991)

Buesa, J.M., Mouridsen, H.T., Van Oosterom, A.T., Verweij, J., Wagener, T., Steward, W., ...

Forty-four of 50 adult patients with advanced soft-tissue sarcoma who had received previous chemotherapy were evaluable for response after treatment with DTIC. The therapeutic schedule consisted of...

Short report: High-dose DTIC in advanced soft-tissue sarcomas in the adult: A phase II study of the E.O.R.T.C. Soft Tissue and Bone Sarcoma Group (1991)

Buesa, J. M., Mouridsen, H. T., Van Oosterom, A. T., Verweij, J., Wagener, T., Steward, W., ...

Forty-four of 50 adult patients with advanced soft-tissue sarcoma who had received previous chemotherapy were evaluable for response after treatment with DTIC. The therapeutic schedule consisted of...

Review of the clinical trials activity of the Soft Tissue and Bone Sarcoma Group of the European Organization for Research and Treatment of Cancer (1988)

Santoro, A, Rouesse, J, Mouridsen, H, Steward, W, ...

Despite the low incidence of sarcomas, the Soft Tissue and Bone Sarcoma Group has established itself as one of the more active cooperative groups of the European Organization for Research and...

Chemotherapy for upper gastrointestinal tumours

Thomas, A, O'Byrne, K, Steward, W

The aim of this review is to identify current chemotherapy treatment for tumours of the oesophagus, stomach, pancreas, and liver. The role of both neoadjuvant, adjuvant, and palliative chemotherapy...

Familiar drugs may prevent cancer

Sharma, R, Gescher, A, O'Byrne, K, Steward, W

Despite positive results in large scale chemoprevention trials, many physicians are unaware of the potential cancer preventive properties of drugs in common usage. The antioestrogen tamoxifen and the...

rhGM-CSF ameliorates neutropenia in patients with malignant glioma treated with BCNU.

Rampling, R., Steward, W., Paul, J., Macham, M. A., Harvey, E., Eckley, D.

Nitrosoureas are the drugs most effective in the treatment of patients with intracerebral malignant glioma. Their limiting toxicity is delayed myelosuppression. A prospective, randomised crossover...

Volunteers or victims: patients' views of randomised cancer clinical trials.

Slevin, M., Mossman, J., Bowling, A., Leonard, R., Steward, W., Harper, P., ...

Randomised clinical trials are essential for the objective evaluation of different treatment strategies in cancer. However, in the field of oncology, very few of the eligible patients are entered...

High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group.

Nielsen, O. S., Dombernowsky, P., Mouridsen, H., Crowther, D., Verweij, J., Buesa, J., ...

The activity and toxicity of single-agent standard-dose doxorubicin were compared with that of two schedules of high-dose epirubicin. A total of 334 chemonaive patients with histologically confirmed...